ONE platform, THREE different
indications, in sequence.
Ecmera is building a new therapeutic layer for oncology.
The first pairing is oxHA with CD44, the receptor through which hyaluronic acid instructs cancer cells to migrate and invade. Other ECM-to-cell pairings are also being explored.
The sequence is deliberate – PROVE, SCALE, and then EXPAND. Each indication has to earn the next.
Prove it where
it is hardest.
Glioblastoma is the most common brain cancer, with around 160,000 new cases diagnosed globally each year. The standard of care, surgery followed by radiotherapy and chemotherapy (TMZ), has changed little in twenty years, and Median Overall Survival (Stupp Protocol) is less than 15 months.
Recurrence is almost universal, and it happens at the margin of the resection, in the matrix in which Ecmera's science is at the heart of it.
Scale it where
the need is greatest.
Pancreatic ductal adenocarcinoma (PDAC) – also known as the ‘silent killer’ – is among the deadliest cancers, with around 460,000 new cases diagnosed globally each year. It is often diagnosed late with poor prognosis and has a Median Overall Survival of less than 12 months.
It is also a tumour known for the dense ECM / matrix that surrounds it.
Expand it to children
and young adults.
Osteosarcoma is a bone cancer that mostly affects children and young adults, with around 13,000 new cases diagnosed globally each year in people under twenty. Its standard of care has barely changed in forty years, and it is recognised as a rare disease whose treatment are often classified in the “Orphan Drug” category.
If the platform works in the ECM-rich soft tissues in the brain and the pancreas, bone is where it shows it can go further.